Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Dominik Steubl

ResearcherPublications, citations & collaboration network

Dominik Steubl is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 114 works, 2,370 citations, an h-index of 29 and an i10-index of 53.

114
Works
2,370
Citations
29
h-index
53
i10-index

How has Dominik Steubl's publication output changed over time?

ScholarIQpublication output · 2008–2023

Output grew200% over the shown period — from 1 works in 2008 to 3 in 2023.

1
1
1
1
1
2
1
3
20082015201620182020202120222023

What are the most-cited papers on Dominik Steubl?

ScholarIQmost cited works
Transcriptional regulation at a HTR1A polymorphism associated with mental illness
Brice Le François, Margaret Czesak, Dominik Steubl, Paul R. Albert
S160566677. 2008184 Citations
Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients
Dominik Steubl, Matthias Block, Victor Herbst, Wolfgang Andreas Nockher, Wolfgang Schlumberger, Robin Satanovskij, Susanne Angermann, Anna-Lena Hasenau, Lynne Stecher, Uwe Heemann, Lutz Renders, Jürgen E. Scherberich
Medicine. 2016175 CitationsOPEN ACCESS
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
João Pedro Ferreira, Faı̈ez Zannad, Stuart Pocock, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Waheed Jamal, Dominik Steubl, Elke Schueler, Milton Packer
Journal of the American College of Cardiology. 2021166 CitationsOPEN ACCESS
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, Julie Green, SJ Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, Susanne Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi
The Lancet Diabetes & Endocrinology. 2023116 CitationsOPEN ACCESS
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Julie Green, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, S Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, A Ali, A Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai
The Lancet Diabetes & Endocrinology. 202394 CitationsOPEN ACCESS

Related on ScholarIQ

Boehringer Ingelheim (Germany)
Institution
Transcriptional regulation at a HTR1A polymorphism associated with mental illness
Paper
Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients
Paper
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Paper
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Paper
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Paper
470M+ articles · free account